Processa Pharmaceuticals, Inc. Increase (Decrease) in Deferred Revenue
Processa Pharmaceuticals, Inc. (PCSA) reported Increase (Decrease) in Deferred Revenue of -$58.16 thousand for the 12-month period ending 2015-12-31, per its 10-K filed 2017-09-25.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2017-09-25
- Processa Pharmaceuticals, Inc. increase (decrease) in deferred revenue for the quarter ending 2015-12-31 was -$22.50K.
- Processa Pharmaceuticals, Inc. increase (decrease) in deferred revenue for the quarter ending 2015-09-30 was -$143.13K.
- Processa Pharmaceuticals, Inc. increase (decrease) in deferred revenue for the quarter ending 2015-06-30 was $22.50K.
- Processa Pharmaceuticals, Inc. increase (decrease) in deferred revenue for the quarter ending 2015-03-31 was $84.96K.
- Processa Pharmaceuticals, Inc. increase (decrease) in deferred revenue for fiscal 2015 was -$58.16K, a 200.00% decline from fiscal 2014.
- Processa Pharmaceuticals, Inc. increase (decrease) in deferred revenue for fiscal 2014 was $58.16K.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|---|
| 2015-12-31 | -$22.50K derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-25 | -$165.63K derived: sum of 2 quarters · filed 2017-09-25 | -$143.13K derived: sum of 3 quarters · filed 2017-09-25 | -$58.16K 10-K · filed 2017-09-25 |
| 2015-09-30 | -$143.13K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-09-08 | -$120.63K derived: sum of 2 quarters · filed 2017-09-08 | -$35.66K 10-Q · filed 2017-09-08 | |
| 2015-06-30 | $22.50K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-30 | $107.46K 10-Q · filed 2017-08-30 | ||
| 2015-03-31 | $84.96K 10-Q · filed 2017-08-07 | |||
| 2014-12-31 | $58.16K 10-K · filed 2017-06-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |